Endometrial Cancer Market Growing Significantly | AstraZeneca, Karyopharm, Evergreen therapeutics, ImmunoGen, Inc., Merck, Tesaro, Inc., Abbott, Roche, Chimerix, Bayer, ImmunoGen, Inc., Incyte, Eli Lilly, Gilead, Genentech Expected to Boost New York, USA, April 03, 2023 (GLOBE NEWSWIRE) -- Endometrial Cancer Market Growing Significantly | AstraZeneca, Karyopharm, Evergreen therapeutics, ImmunoGen, Inc., Merck, Tesaro, Inc., Abbott,...

Onconova Therapeutics to Provide Corporate Update and Announce Fourth Quarter and Full Year 2022 Financial Results on March 16, 2023 NEWTOWN, Pa., March 09, 2023 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), (“Onconova”), a clinical-stage biopharmaceutical company focused on discovering and developing novel...

Onconova Therapeutics Announces Plans for a Phase 1/2a Trial of Narazaciclib Combined with Letrozole in Endometrial Cancer, Reports Third Quarter 2022 Financial Results, and Provides a Business Update Initiation of Phase 1/2a endometrial cancer trial expected in 1Q23; preliminary data expected 4Q23 Conference call and live webcast at 4:30 p.m. ET today NEWTOWN, Pa., Nov. 14, 2022 (GLOBE...

Sermonix Pharmaceuticals Project With Huntsman Cancer Institute Researcher to Investigate Potential Effects of Lasofoxifene on ESR1 Mutations in Endometrial Cancer COLUMBUS, Ohio, April 21, 2021 (GLOBE NEWSWIRE) -- Sermonix Pharmaceuticals Inc., a privately held biopharmaceutical company developing innovative therapeutics to treat ESR1-mutated metastatic...

TESARO Initiates Registrational Development Program for Anti-PD-1 Antibody TSR-042 TSR-042 is the first TESARO immuno-oncology candidate to enter a registration programOngoing clinical trial expanded to enroll patients with endometrial cancerPatient-centric administration...